Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect.
Zerumbone, a natural dietary lipophilic compound with low water solubility (1.296 mg/L at 25°C) was used in this investigation. The zerumbone was loaded into nanostructured lipid carriers using a hot, high-pressure homogenization technique. The physicochemical properties of the zerumbone-loaded nanostructured lipid carriers (ZER-NLC) were determined. The ZER-NLC particles had an average size of 52.68 ± 0.1 nm and a polydispersity index of 0.29 ± 0.004 μm. Transmission electron microscopy showed that the particles were spherical in shape. The zeta potential of the ZER-NLC was -25.03 ± 1.24 mV, entrapment efficiency was 99.03%, and drug loading was 7.92%. In vitro drug release of zerumbone from ZER-NLC was 46.7%, and for a pure zerumbone dispersion was 90.5% over 48 hours, following a zero equation. Using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in human T-cell acute lymphoblastic leukemia (Jurkat) cells, the half maximal inhibitory concentration (IC50) of ZER-NLC was 5.64 ± 0.38 μg/mL, and for free zerumbone was 5.39 ± 0.43 μg/mL after 72 hours of treatment. This study strongly suggests that ZER-NLC have potential as a sustained-release drug carrier system for the treatment of leukemia.
Department of Microbiology and Pathology, Faculty of Veterinary Medicine, University Putra Malaysia, Serdang, Selangor, Malaysia.
Heshu Sulaiman
HS
Rahman
Abdullah
A
Rasedee
Chee Wun
CW
How
Ahmad Bustamam
AB
Abdul
Nazariah Allaudin
NA
Zeenathul
Hemn Hassan
HH
Othman
Mohamed Ibrahim
MI
Saeed
Swee Keong
SK
Yeap
D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D002470:Cell Survival / Q000187:drug effects; D003460:Crystallization; D004337:Drug Carriers / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D004355:Drug Stability; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019169:Jurkat Cells; D007938:Leukemia; D008055:Lipids / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D012717:Sesquiterpenes / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology; D014961:X-Ray Diffraction
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008055:Lipids; D012717:Sesquiterpenes; C403304:zerumbone
leukemia; nanostructured lipid carrier; zerumbone